

Supplementary figure legends

Supplementary figure 1. FZU-0025-065 moderately induce apoptosis in TNBC cells.

(A) FZU-0025-065 induces apoptosis in HCC1806, but not in MDA-MB-468 cells. FZU-0025-065, FZU-0038-063 or DMSO treated cells were collected for Annexin V staining. The quantitative results of HCC1806 and MDA-MB-468 were shown on the right.

(B) HCC1806 and MDA-MB-468 cells were treated with 9 μ M FZU-0025-065, FZU-0038-063 or DMSO for indicated time. The cells were then collected for WB analysis. β -actin was detected as the loading control.

Supplementary figure 2. FZU-0025-065 suppresses TNBC cell cycle progression partially through inhibiting AKT signaling.

Ectopic overexpression of AKT partially rescued FZU-0025-056 caused reduction of cyclin D1 and CDK4, it also partially rescued FZU-0025-056 induced up-regulation of p21 and p27.

Supplementary figure 3. FZU-0025-065 suppresses HCC1806 cell growth in xenograft mouse model

HCC1806 cells were injected into the fat pat of female Balb/c nude mice. When the average tumor size reached about 50 mm³ after inoculation, the mice were randomly distributed into two groups: vehicle control and 20 mg/kg FZU-0025-065. Tumors were measured with a caliper every other day and were collected 2 weeks after drug treatment.



Supplementary figure 4. Alpelisib suppresses AKT activation and regulates cell cycle associated proteins' expression

(A) Alpelisib suppresses AKT activation.

(B) Alpelisib inhibits TNBC cell survival. HCC1806 and MDA-MB-468 cells were

treated with Alpelisib, FZU-0025-065 or DMSO control for indicated time and at indicated dosages. Cells were then fixed for SRB assay.

(C-D) Alpelisib suppresses the expression cyclin B1, cyclin D1 and CDK4. HCC1806 and MDA-MB-468 cells were treated with indicated compounds or DMSO control for indicated time and at indicated dosages. α,β -tubulin were detected as loading control.

A**B****Figure S1**




Figure S2




Figure S3




























Figure S4

Supplementary Table 1. Structure of isochromanoindolenine compounds

Compound ID	Formula	Molecular Weight	Chemical Structure	Solubility
FZU-0025-065	C ₂₅ H ₂₁ ClN ₂ O ₆ S	512.96		DMSO
FZU-0038-063	C ₁₈ H ₁₇ ClN ₂ O ₂ S	360.07		DMSO
FZU-0025-044	C ₂₄ H ₂₀ N ₂ O ₆ S	464.49		DMSO
FZU-0025-046	C ₂₇ H ₂₆ N ₂ O ₆ S	506.57		DMSO
FZU-0025-048	C ₁₉ H ₁₈ N ₂ O ₆ S	402.42		DMSO
FZU-0025-101	C ₁₉ H ₁₇ ClN ₂ O ₆ S	436.86		DMSO
FZU-0038-132	C ₂₀ H ₁₈ N ₂ O ₅	366.37		DMSO
FZU-0025-102	C ₂₀ H ₁₇ ClN ₂ O ₅	400.82		DMSO
FZU-0038-130	C ₂₀ H ₁₈ N ₂ O ₆	382.37		DMSO

FZU-0025-103	C 20 H 17 Cl N 2 O 6	416.81		DMSO
FZU-0021-263	C 25 H 22 N 2 O 6 S	478.52		DMSO
FZU-0025-066	C 25 H 21 F N 2 O 6 S	496.51		DMSO
FZU-0025-070	C 26 H 24 N 2 O 6 S	492.55		DMSO
FZU-0025-097	C 25 H 21 F N 2 O 6 S	496.51		DMSO
FZU-0025-096	C 26 H 24 N 2 O 6 S	492.55		DMSO
FZU-0025-079	C 24 H 20 N 2 O 6 S	464.49		DMSO
FZU-0025-080	C 24 H 19 Cl N 2 O 6 S	498.93		DMSO
FZU-0025-081	C 25 H 22 N 2 O 7 S	494.52		DMSO
FZU-0025-082	C 20 H 18 N 2 O 5	366.37		DMSO
FZU-0025-083	C 20 H 17 Cl N 2 O 5	400.82		DMSO

FZU-0025-085	C 20 H 18 N 2 O6	382.37		DMSO
FZU-0025-086	C 20 H 17 ClN 2 O1	416.81		DMSO
FZU-0021-258	C 23 H 24 N 2 O6	424.45		DMSO
FZU-0025-088	C 26 H 21 N 3 O5	455.47		DMSO